Unanimous HOLD across all three analysts, Research Manager, and Trader is warranted given the ~25x forward P/E requiring two stacked conditions (AI acquisition integration success and premium multiple re-rating) that Q2's 68% operating income collapse undermines. The $115 trailing stop is preferred over the Neutral's $100 stop, providing a ~6.3% buffer below the 200 SMA for normal backtest volatility while preserving capital discipline. Size any post-Q3 confirmation add at ≤50% of normal allocation; avoid chasing above $126 without volume confirmation.